Followers | 20 |
Posts | 5331 |
Boards Moderated | 0 |
Alias Born | 01/04/2012 |
Tuesday, January 22, 2019 4:57:45 AM
Effects of testosterone therapy for women: a systematic review and meta-analysis protocol
Discussion:
Despite the prescribing of testosterone to women which is occurring globally [21], primarily for the treatment of low libido [22], internationally agreed guidelines for the use of testosterone in women are lacking. This systematic review, with meta-analysis, will provide a comprehensive systematic analysis of clinical studies that have examined the effects of systematic testosterone therapy in women on sexual function, cardiovascular events, metabolic parameters, musculoskeletal health and wellbeing. Strengths of this review include searching all the major clinical medicine data bases and the references of retrieved articles, not limiting our search to English publications, and recontacting authors for missing data. Although we cannot fully anticipate the limitations of our review, it is possible that we will not be able to get access to all studies published in languages other than English. This review will provide a critical basis for the development of evidence-based clinical practice guidelines for the indications and contra-indications to therapy, the benefits and risks of therapy, the areas of clinical uncertainty and the assessment and monitoring of patients. Thus, it is the first step towards filling this important gap in women’s health care. The findings of this review will be presented at international conferences and published in the relevant journal/s.
This was recently published in Systemic Reviews but was submitted in August 2018.
Systemic Review
Recent ANIP News
- ANI Pharmaceuticals to Participate at Two Upcoming Healthcare Conferences • GlobeNewswire Inc. • 05/01/2024 08:30:00 PM
- ANI Pharmaceuticals to Discuss First Quarter 2024 Financial Results on May 10, 2024, at 8:30 a.m. ET • GlobeNewswire Inc. • 04/18/2024 08:05:00 PM
- ANI Pharmaceuticals Announces the Launch of Baclofen Oral Suspension • GlobeNewswire Inc. • 04/09/2024 10:50:00 AM
- ANI Pharmaceuticals Recognizes Sarcoidosis Awareness Month and Patients Living with Sarcoidosis • GlobeNewswire Inc. • 04/04/2024 10:50:00 AM
- ANI Pharmaceuticals to Participate at the Piper Sandler Spring Biopharma Symposium • GlobeNewswire Inc. • 04/03/2024 10:50:00 AM
- ANI Pharmaceuticals Announces the Launch of Levofloxacin Oral Solution, USP • GlobeNewswire Inc. • 03/27/2024 10:50:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/09/2024 12:25:12 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/08/2024 10:59:27 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/08/2024 09:26:44 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 02:42:07 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 02:21:15 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 02:16:48 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 02:11:59 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/07/2024 09:05:40 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/06/2024 10:58:36 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/06/2024 10:31:15 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/06/2024 09:29:43 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 09:24:34 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/05/2024 10:00:05 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/05/2024 12:18:43 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/01/2024 10:18:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/01/2024 10:12:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/01/2024 10:09:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/01/2024 10:06:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/01/2024 10:03:56 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM